Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56).
Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment.
You may not be if
Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported.
Participating in an interventional clinical trial at the time of ICF signature.
Known allergic reactions to components of tagraxofusp.
